The ANGPTL4 inhibitor, MAR001, significantly reduced fasting TG levels in adults with hypertriglyceridaemia (HTG) in PART A of the Phase 2b TYDAL-TIMI 78 trial reported as a late breaker at AHA Scientific Sessions 2026 and published simultaneously in the New England Journal of Medicine.1,2
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
